Epicentrx, Inc.

Leland Stanford Junior University

Alliant Techsystems Inc.

Orbital Atk, Inc.

Dana-farber-cancer Institute Inc.

Radiorx, Inc.

Northrop Grumman Systems Corporation

Children's Medical Center Corporation

Children's Hospital

Susan Knox

Louis F Cannizzo

Shoucheng Ning

Stephen P Velarde

Kirstin F Warner

Robert B Wardle

Mark David Bednarski

Gordon James Freeman

Dale T Umetsu

Jennifer L Jones

Rosemarie Dekruyff

Lynn M Oehler, Legal Representative

Bryan Husbeck

Bryan T Oronsky

Jan Scicinski

Frans A Kuypers

Pedro Cabrales

William Fitch

Sandra Larkin

Chad Brouse

Marcel Fens

Mark D Bednarski

Kirstin Warner

Robert Wardle

Stephen Velarde

The present invention provides cyclic nitro compound, pharmaceutical compositions of cyclic nitro compounds and methods of using cyclic nitro compounds and/or pharmaceutical compositions thereof to treat or prevent diseases or disorders characterized by abnormal cell proliferation, such as cancer, inflammation, cardiovascular disease and autoimmune disease.

Cyclic nitro compounds, pharmaceutical compositions thereof and uses thereof

The invention provides methods, compositions, and medical kits comprising a nitrite-reductase promoter, such as an allosteric modulator of hemoglobin, for use in treating medical disorders and preservation of blood products. In one aspect, the invention provides methods, compositions, and medical kits comprising an inorganic nitrite salt and a nitrite-reductase promoter, such as an allosteric modulator of hemoglobin, for use in treating medical disorders, such as cancer, cardiovascular disorders, ischemic conditions, hemolytic conditions, and bacterial infections. Exemplary inorganic nitrite salts include sodium nitrite and arginine nitrite. Exemplary allosteric modulators of hemoglobin described herein include alkyl-substituted and acyl-substituted di-nitroheterocycles.

Methods and compositions comprising a nitrite-reductase promoter for treatment of medical disorders and preservation of blood products

A genetic locus and corresponding family of proteins associated with regulation of immune function and cell survival are provided. These genes encode cell surface molecules with conserved IgV and mucin domains. The locus comprising the TIM family is genetically associated with immune dysfunction, including asthma. Furthermore, the TIM gene family is located within a region of human chromosome 5 that is commonly deleted in malignancies and myelodysplastic syndrome. Polymorphisms in the gene sequences are associated with the development of airway hyperreactivity and allergic inflammation, and T cell production of IL-4 and IL-13. The proteins include the human hepatitis A cellular receptor, hHAVcr-1.

Modulation of TIM receptor activity in combination with cytoreductive therapy

The invention features methods and selenium-containing compositions for treating a neoplastic disease in a subject. In particular, the invention features methods for enhancing sensitivity of a tumor to cancer therapy by treating the tumor with an inorganic selenium-containing (iSe) compound and with a cancer therapy, particularly a cancer therapy that also affects the cellular redox status of a tumor cell (e.g., radiation).

Methods for treating a neoplastic disease in a subject using inorganic selenium-containing compounds

The present invention provides O-nitro compounds, pharmaceutical compositions of O-nitro compounds and methods of using O-nitro compounds and/or pharmaceutical compositions thereof to treat or prevent diseases or disorders characterized by abnormal cell proliferation, such as cancer, inflammation, cardiovascular disease and autoimmune disease.

O-nitro compounds and pharmaceutical compositions including same

Pharmaceutical compositions of O-nitro compounds

Growing community of inventors

Stanford, CA, United States of America

Susan Knox